PHARMANUTRA SPA (PHN.MI) Stock Price & Overview

BIT:PHN • IT0005274094

Current stock price

78.6 EUR
0 (0%)
Last:

The current stock price of PHN.MI is 78.6 EUR. Today PHN.MI is down by 0%. In the past month the price increased by 17.14%. In the past year, price increased by 61.9%.

PHN.MI Key Statistics

52-Week Range38.75 - 80.4
Current PHN.MI stock price positioned within its 52-week range.
1-Month Range66.1 - 80.4
Current PHN.MI stock price positioned within its 1-month range.
Market Cap
760.848M
P/E
59.10
Fwd P/E
38.78
EPS (TTM)
1.33
Dividend Yield
1.27%

PHN.MI Stock Performance

Today
0%
1 Week
+0.90%
1 Month
+17.14%
3 Months
+34.36%
Longer-term
6 Months +63.75%
1 Year +61.90%
2 Years +46.10%
3 Years +55.18%
5 Years +111.29%
10 Years N/A

PHN.MI Stock Chart

PHARMANUTRA SPA / PHN Daily stock chart

PHN.MI Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PHN.MI. When comparing the yearly performance of all stocks, PHN.MI is one of the better performing stocks in the market, outperforming 89% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PHN.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI. PHN.MI gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHN.MI Earnings

On March 17, 2026 PHN.MI reported an EPS of 0.63 and a revenue of 37.08M. The company beat EPS expectations (0.61% surprise) and beat revenue expectations (0.59% surprise).

Next Earnings DateMay 11, 2026
Last Earnings DateMar 17, 2026
PeriodQ4 / 2025
EPS Reported€0.63
Revenue Reported37.083M
EPS Surprise 0.61%
Revenue Surprise 0.59%

PHN.MI Forecast & Estimates

7 analysts have analysed PHN.MI and the average price target is 88.74 EUR. This implies a price increase of 12.9% is expected in the next year compared to the current price of 78.6.

For the next year, analysts expect an EPS growth of 43.02% and a revenue growth 15.93% for PHN.MI


Analysts
Analysts82.86
Price Target88.74 (12.9%)
EPS Next Y43.02%
Revenue Next Year15.93%

PHN.MI Groups

Sector & Classification

Index Membership

PHN.MI Financial Highlights

Over the last trailing twelve months PHN.MI reported a non-GAAP Earnings per Share(EPS) of 1.33. The EPS decreased by -14.74% compared to the year before.


Income Statements
Revenue(TTM)100.20M
Net Income(TTM)24.16M
Industry RankSector Rank
PM (TTM) 13.39%
ROA 20.17%
ROE 36.55%
Debt/Equity 0.24
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%-37.6%
EPS 1Y (TTM)-14.74%
Revenue 1Y (TTM)21.13%

PHN.MI Ownership

Ownership
Inst Owners15.13%
Shares9.68M
Float3.30M
Ins Owners65.02%
Short Float %N/A
Short RatioN/A

About PHN.MI

Company Profile

PHN logo image Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Company Info

IPO: 2017-07-18

PHARMANUTRA SPA

Via delle Lenze n. 216/B

Pisa PISA IT

Employees: 128

PHN Company Website

PHN Investor Relations

Phone: 390507846500

PHARMANUTRA SPA / PHN.MI FAQ

What does PHN do?

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.


What is the stock price of PHARMANUTRA SPA today?

The current stock price of PHN.MI is 78.6 EUR.


What is the dividend status of PHARMANUTRA SPA?

PHARMANUTRA SPA (PHN.MI) has a dividend yield of 1.27%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of PHN stock?

PHN.MI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


On which exchange is PHN.MI stock listed?

PHN.MI stock is listed on the Euronext Milan exchange.


Should I buy PHN stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHN.MI.